Similarly, for renal cancer, EGFR and TIM-1 are established tumor biomarkers for which immunotherapy has been proposed [44–46] and a phase I clinical trial with the goal to treat renal cell carcinoma with a TIM-1 targeting antibody indicated efficacy with manageable adverse effects [47]. This evidence concerns the gene HAVCR1 and neoplasm.